2. Patient Presentation

3. PRIMO Study Incidence of Muscle Adverse Effects

4. Therapy for Statin Intolerance

5. Ezetimibe Trials

6. Population Studies PCSK9 Loss-of-Function Mutations

7. PCSK9-Directed Therapies in Development

8. GAUSS-1 Phase 2 Evolocumab in Statin-Intolerant Patients

9. GAUSS-1 % Change in LDL-C From Baseline at Week 12

10. GAUSS-2 Study Design Phase 3 Efficacy and Safety Study of Evolocumab in Statin-Intolerant Patients

11. GAUSS-2 % Change in LDL-C From Baseline at Week 12

12. GAUSS-2 Safety and Tolerability

13. Abbreviations

14. References

15. References (cont)

16. References (cont)